MIRM · earnings call history
Mirum Pharmaceuticals Q2 FY26 — Strong Commercial Performance and Pipeline Progress Amidst Regulatory Delay for Volixibat in PSC
Read the briefMirum Pharmaceuticals Q1 FY26 — Strong Commercial Growth and Pipeline Expansion
Read the briefMirum Pharmaceuticals Q4 FY25 — Strong Sales Growth and Pivotal Pipeline Readouts Ahead
Read the briefBrowse all US companies on the earnings-call register.